Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 862 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Deficit/Hyperactivity Disorder Clear all
Completed Phase 2 Interventional

Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

NCT00315276
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Little Rock, Arkansas • Lafayette, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Not applicable Interventional Results available

Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD

NCT00989950
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, INSOMNIA
Interventions
Daytrana
Drug
Lead sponsor
Cox Health Systems
Other
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 23, 2026, 8:34 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Clinical Applications of High-Frequency Oscillations

NCT00600717
View directory record Official record
Conditions
Epilepsy, Migraine, Headache, Pain, Autism, Cerebral Palsy, Brain Development, Traumatic Brain Injury, ADHD - Attention Deficit Disorder With Hyperactivity, Mental Health
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 69 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 23, 2026, 8:34 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Nutrient Intake in Children With Attention Deficit Hyperactivity Disorder

NCT00011466
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 13 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 8:34 AM EDT
Not listed Not applicable Interventional

A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medications in Children With ADHD

NCT04189562
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
SMS Intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Not applicable Interventional Results available

Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication

NCT00561340
View directory record Official record
Conditions
ADHD
Interventions
Pediasure, Nutritional counseling
Dietary Supplement · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 9 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional

Long-Term Lithium Treatment for Aggressive Conduct Disorder

NCT00000385
View directory record Official record
Conditions
Conduct Disorder, Aggression
Interventions
Lithium, Placebo
Drug
Lead sponsor
Drexel University
Other
Eligibility
9 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 23, 2026, 8:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Cognition and Control in Youths

NCT03393390
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
Interventions
Clinical Assessment Visit, fMRI scan
Diagnostic Test · Other
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

NCT00264797
View directory record Official record
Conditions
ADHD, Substance Abuse
Interventions
Methylphenidate (OROS-MPH), Methylphenidate (OROS-MPH) - Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
13 Years to 18 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Denver, Colorado • Jacksonville, Florida • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2013 · Synced Oct 23, 2026, 8:34 AM EDT
Completed No phase listed Observational

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

NCT03233867
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Not applicable Interventional Results available

Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)

NCT01740206
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine and/or methylphenidate, Hold stimulant medication
Drug · Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 23, 2026, 8:34 AM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01274221
View directory record Official record
Conditions
ADHD
Interventions
SPD489, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Bradenton, Florida • Overland Park, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 23, 2026, 8:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Mediodorsal Thalamus Representations Underlying Human Cognitive Flexibility

NCT07217652
View directory record Official record
Conditions
Schizophrenia, Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions
High-resolution fMRI during working memory, cognitive control, and decision-making tasks
Other
Lead sponsor
Kai Hwang
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory

NCT00530257
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Placebo, OROS-methylphenidate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 23, 2026, 8:34 AM EDT
Recruiting Not applicable Interventional

External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms

NCT07214545
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity (ADHD), Autism Spectrum Disorder (ASD)
Interventions
Trigeminal Nerve Stimulation, Sham Trigeminal Nerve Stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

Atomoxetine, Placebo and Parent Management Training in Autism

NCT00844753
View directory record Official record
Conditions
Autism, Pervasive Development Disorder, Asperger's Disorder, Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine, Placebo, Parent Management Training
Drug · Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
5 Years to 14 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Rochester, New York • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 23, 2026, 8:34 AM EDT
Suspended Phase 3 Interventional

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

NCT05924594
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions
CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parents at the Center: Information Management in ADHD - Clinical Trial

NCT00543257
View directory record Official record
Conditions
Health Literacy, Attention Deficit Disorder With Hyperactivity, Computer Literacy, Information Management, Parents
Interventions
Use of paper forms to write down information, Computer
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modulation of Frontoparietal Dynamics Underlying Adolescent Working Memory Deficits

NCT05119660
View directory record Official record
Conditions
ADHD
Interventions
Intermittent Theta Burst Stimulation
Device
Lead sponsor
Bradley Hospital
Other
Eligibility
13 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Recruiting Phase 3 Interventional

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

NCT07717879
View directory record Official record
Conditions
ADHD
Interventions
Solriamfetol Dose A, Solriamfetol Dose B, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

NCT05279313
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Centanafadine Hydrochloride
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
84
States / cities
Dothan, Alabama • Saraland, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Not applicable Interventional

Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD

NCT00631280
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Choice, Recommendation
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00528697
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, atomoxetine, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
6 Years to 12 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • El Centro, California • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 23, 2026, 8:34 AM EDT